Taking the Road Less Traveled: Following Molecular Trail Markers
- PMID: 35960159
- DOI: 10.1158/1078-0432.CCR-22-1623
Taking the Road Less Traveled: Following Molecular Trail Markers
Abstract
Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.
©2022 American Association for Cancer Research.
Comment on
-
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.Clin Cancer Res. 2022 Oct 14;28(20):4456-4465. doi: 10.1158/1078-0432.CCR-21-4183. Clin Cancer Res. 2022. PMID: 35443055 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
